Predictive value of systemic immuno-inflammatory index on the efficacy of Tislelizumab in combination with Gemcitabine and Cisplatin in patients with muscle-invasive bladder carcinoma after radical surgery
10.3969/j.issn.1009-8291.2025.07.005
- VernacularTitle:全身免疫炎症指数对肌层浸润性膀胱癌根治术后辅助替雷利珠单抗联合吉西他滨和顺铂疗效的预测价值
- Author:
Jiacheng LU
1
;
Xu QIN
;
Hailong LI
;
Rumin WEN
Author Information
1. 徐州医科大学附属医院泌尿外科,江苏徐州 221002;徐州医科大学研究生院,江苏徐州 221002
- Publication Type:Journal Article
- Keywords:
bladder carcinoma;
systemic immuno-inflammatory index;
adjuvant treatment;
Tislelizumab;
Gemcitabine;
Cisplatin
- From:
Journal of Modern Urology
2025;30(7):576-581
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the predictive value of systemic immuno-inflammatory index(SII)and the amplitude of change(Dclta-SII)on the efficacy of adjuvant treatment with Tislelizumab(T)in combination with Gemcitabine and Cisplatin(GC)in patients with muscle-invasive bladder carcinoma(MIBC)after radical surgery.Methods A total of 47 MIBC patients undergoing radical surgery in the Affiliated Hospital of Xuzhou Medical University during Jun.2018 and Jun.2022 were enrolled.All patients received T+GC therapy.Baseline SII before treatment(Pre-SII)and SII after 3 cycles(Post-SII)were collected,and Delta-SII was calculated.The sensitivity and specificity of Pre-SII and Delta-SII were measured using receiver operating characteristic(ROC)curves,and the best cut-off values were determined.The recurrence-free survival(RFS)rate was analyzed with Kaplan-Meier method.The risk factors of RFS were investigated with univariate and multivariate Cox proportional hazard models.Results ROC curves indicated that the best cut-off values of Pre-SII and Delta-SII were 516.31 and 0.176,respectively.The low Pre-SII group(＜516.31)and high Delta-SII group(≥0.176)were associated with longer RFS(HR=1.951,95％CI:1.063-3.581,P=0.029;HR=3.892,95％CI:2.010-7.534,P＜0.001).Cox proportional hazard models showed that high Pre-SII(≥516.31),low Delta-SII(≤0.176),T3-T4 stage,Nx stage and tumor size＞3 cm were independent risk factors for tumor recurrence.Conclusion In MIBC patients receiving T+GC therapy,the amplitude of change before treatment and after 3 cycles of treatment can be used as valuable predictors of clinical efficacy.
